TABLE 2 Open in new tab Ongoing Clinical...

TABLE 2

Ongoing Clinical Trials: therapeutics against cytokine storm (up to May 6, 2020)

Register Number	Title	Drugs/Strategies	Therapeutic Target	Study design	Samples	Phase
ChiCTR2000029765	A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	RCT	188	4
ChiCTR2000030196	A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	Single arm	60	2
NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	Tocilizumab	Anti-IL-6 Receptor	Single arm	330	2
NCT04320615	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	330	3
NCT04310228	Favipiravir Combined with Tocilizumab in the Treatment of Corona Virus Disease 2019	Tocilizumab	Anti-IL-6 Receptor	RCT	150	N/A
NCT04306705	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19	Tocilizumab	Anti-IL-6 Receptor	Cohort study	120	N/A
NCT04315480	Tocilizumab for SARS-CoV2 Severe Pneumonitis	Tocilizumab	Anti-IL-6 Receptor	Single arm	30	2
NCT04331795	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	Tocilizumab	Anti-IL-6 Receptor	RCT	50	2
NCT04331808	CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)	Tocilizumab	Anti-IL-6 Receptor	RCT	240	2
NCT04332913	Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia	Tocilizumab	Anti-IL-6 Receptor	Cohort study	30	N/A
NCT04335071	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	RCT	100	2
NCT04346355	Efficacy of Early Administration of Tocilizumab in COVID-19 Patients	Tocilizumab	Anti-IL-6 Receptor	RCT	398	2
NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	Tocilizumab	Anti-IL-6 Receptor	RCT	300	3
NCT04359667	Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab	Tocilizumab	Anti-IL-6 Receptor	Case	30	N/A
NCT04361032	Assessment of Efficacy and Safety of Tocilizumab Compared to Deferoxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia	Tocilizumab/Deferoxamine	Anti-IL-6 Receptor	RCT	260	3
NCT04361552	Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)	Tocilizumab	Anti-IL-6 Receptor	RCT	180	3
NCT04363736	A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	100	2
NCT04363853	Tocilizumab Treatment in Patients With COVID-19	Tocilizumab	Anti-IL-6 Receptor	Single arm	200	2
NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	Tocilizumab	Anti-IL-6 Receptor	Single arm	200	2
NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	379	3
NCT04322773	Anti-il6 Treatment of Serious COVID-19 Disease with Threatening Respiratory Failure	Tocilizumab + Sarilumab	Anti-IL-6 Receptor	RCT	200	2
NCT04345445	Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients with High Risk of Progression	Tocilizumab or Corticosteroids	Anti-IL-6 Receptor Glucocorticoid	RCT	310	3
NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	Sarilumab	Anti-IL-6 Receptor	RCT	400	3
NCT04324073	Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI	Sarilumab	Anti-IL-6 Receptor	RCT	240	3
NCT04357808	Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)	Sarilumab	Anti-IL-6 Receptor	RCT	30	2
NCT04357860	Clinical Trial of Sarilumab in Adults With COVID-19	Sarilumab	Anti-IL-6 Receptor	RCT	120	2
NCT04359901	Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design	Sarilumab	Anti-IL-6 Receptor	RCT	120	2
NCT04322188	An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection	Siltuximab	Anti-IL-6	Case-Control	50	N/A
NCT04343989	A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients with Life-threatening COVID-19 Infection	Clazakizumab	Anti-IL-6	RCT	30	2
NCT04348500	Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease	Clazakizumab	Anti-IL-6	RCT	60	2
NCT04363502	Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	Clazakizumab	Anti-IL-6	RCT	30	2
ChiCTR2000030196	A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)	Conventional therapy+ Tocilizumab	Anti-IL-6R	Single arm	60	2
NCT04362813	Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia	Canakinumab	Anti-IL-1β	RCT	450	3
NCT04365153	Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19	Canakinumab	Anti-IL-1β	RCT	45	2
NCT04362111	Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19	Anakinra	Anti-IL-1 Receptor	RCT	20	3
NCT04357366	suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)	Anakinra or trimethoprim/sulfamethoxazole	Anti-IL-1 Receptor or Anti-inflammation	Single arm	100	2
NCT04364009	Anakinra for COVID-19 Respiratory Symptoms	Anakinra	Anti-IL-1 Receptor	RCT	240	3
NCT04366232	Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)	Anakinra+ Ruxolitinib	Anti-IL-1 Receptor+ JAK inhibitor	RCT	50	2
NCT04330638	Treatment of COVID-19 Patients with Anti-interleukin Drugs	Anakinra+ Siltuximab+ Tocilizumab	IL-1 receptor Antagonist+ Anti-IL-6+ Anti-IL-6 Receptor	RCT	342	3
ChiCTR2000030089	A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)	Adalimumab	Anti-TNF-alpha	RCT	60	4
ChiCTR2000030580	Efficacy and safety of adamumab combined with tozumab in severe and critical patients with novel coronavirus pneumonia (COVID-19)	Adalimumab and Tocilizumab	Anti-TNF-alpha Anti-IL-6 Receptor	RCT	60	4
NCT04324021	Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.	Emapalumab and Anakinra	Anti-IFN-γ IL-1 receptor Antagonist	RCT	54	3
ChiCTR2000030703	A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)	Ixekizumab	Anti-IL-17A	RCT	40	0
NCT04347226	Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19	BMS-986253	Anti-IL-8	RCT	138	2
NCT04275245	Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia	Humanized Meplazumab	Anti-CD147	Single arm	20	2
NCT04337216	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients with Severe COVID-19 Pneumonia and Systemic Hyper-inflammation	Mavrilimumab	Anti-GM-CSF-R	Single arm	10	2
NCT04341116	Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)	Anti-GM-CSF Monoclonal Antibody	Anti-GM-CSF	RCT	144	3
NCT04343651	Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19	Leronlimab	CCR5 blockading	RCT	75	2
NCT04347239	Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)	Leronlimab	CCR5 blockading	RCT	390	2
ChiCTR2000030262	Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)	type I interferon and TFF2	Boost innate resistance Anti-inflammatory peptide	RCT	30	0
ChiCTR2000029572	Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a randomized controlled clinical trial	Umbilical cord blood mononuclear cells	Anti-inflammatory, Anti-fibrotic	RCT	30	0
ChiCTR2000029606	Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)	Human Menstrual Blood-Derived Stem Cells	Anti-inflammatory, Anti-fibrotic	RCT	63	0
ChiCTR2000029990	Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)	Mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	RCT	120	2
ChiCTR2000030116	Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)	Human umbilical cord mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	CCT	16	N/A
ChiCTR2000030866	Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)	Human umbilical cord derived mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	Single arm	30	0
NCT04299152	Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2	Stem Cell	Immune suppression	RCT	20	2
NCT04333368	Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS	Umbilical Cord-derived Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	RCT	60	2
NCT04345601	Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)	Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	Single arm	30	1
NCT04361942	Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)	Allogeneic Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	RCT	24	2
NCT04366063	Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome	Mesenchymal Stem Cell	Anti-inflammatory, Anti-fibrotic	RCT	60	3
NCT04366830	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection	EAP+MSCs	Anti-inflammatory, Anti-fibrotic	N/A	N/A	N/A
NCT04371393	MSCs in COVID-19 ARDS	MSCs	Anti-inflammatory, Anti-fibrotic	RCT	300	3
ChiCTR2000029898	A Randomized, Open-label, Parallel, Controlled Trial for Evaluation of the Efficacy and Safety of Chloroquine Phosphate in the treatment of Severe Patients with Novel Coronavirus Pneumonia (COVID-19)	Chloroquine Phosphate	Immune suppression	RCT	100	4
NCT04323631	Hydroxychloroquine for the Treatment of Patients with Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	Hydroxychloroquine	Immune suppression	RCT	1116	1
NCT04323527	Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2	Chloroquine Diphosphate	Immune suppression	RCT	440	2
NCT04358068	Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19	Hydroxychloroquine +Azithromycin	Anti-inflammation	RCT	2000	2
NCT04358081	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease	Hydroxychloroquine+ Monotherapy+ Azithromycin	Anti-inflammation	RCT	444	3
NCT04362332	Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19	Chloroquine+ Hydroxychloroquine	Anti-inflammation	RCT	950	4
ChiCTR2000029757	Convalescent plasma for the treatment of severe novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial	Convalescent plasma	Convalescent plasma	RCT	200	0
ChiCTR2000029850	Study for convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)	Convalescent plasma	Convalescent plasma	CCT	20	0
ChiCTR2000030010	A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)	Anti-SARS-CoV-2 virus inactivated plasma	Convalescent plasma	RCT	100	N/A
ChiCTR2000030929	A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)	Anti-SARS-CoV-2 virus inactivated plasma	Convalescent plasma	RCT	60	N/A
NCT04346446	Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients	Convalescent Plasma in severe COVID-19 Patients	Convalescent Plasma	RCT	20	2
NCT04347681	Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19	Convalescent Plasma	Convalescent Plasma	CCT	40	2
NCT04353206	Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure	Convalescent Plasma in ICU Patients	Convalescent plasma	Single arm	90	1
NCT04359810	Plasma Therapy of COVID-19 in Critically Ill Patients	Convalescent Plasma	Convalescent plasma	RCT	105	2
ChiCTR2000030475	Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)	Cytosorb	Broad Cytokine/Toxin Removal	Single arm	19	0
NCT04324528	Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	Cytokine Adsorption+ Extracorporeal Membrane Oxygenation	Broad Cytokine/Toxin Removal	Case reports	30	R/A
NCT04344080	Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19	CytoSorb	Broad Cytokine/Toxin Removal	RCT	24	N/A
NCT04358003	Plasma Adsorption in Patients With Confirmed COVID-19	Plasma Adsorption	Broad Cytokine/Toxin Removal	Single arm	2000	N/A
NCT04374149	Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS	Plasma Exchange	Broad Cytokine/Toxin Removal	CCT	20	2
NCT04374539	Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial	Plasma Exchange	Broad Cytokine/Toxin Removal	RCT	116	2
NCT04273581	The Efficacy and Safety of Thalidomide Combined with Low-dose Hormones in the Treatment of Severe COVID-19	Thalidomide and Interferon-alpha	Prevent lung injury Boost Innate resistance	RCT	40	2
NCT04293887	Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients	IFN-α2β	Boost Innate Resistance	RCT	328	1
NCT04343768	An Investigation into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial	Interferon Beta 1a or Interferon Beta 1b	Boost Innate Resistance	RCT	60	4
NCT04325061	Efficacy of Dexamethasone Treatment for Patients with ARDS Caused by COVID-19	Dexamethasone	Anti-inflammatory	RCT	200	4
NCT04347980	Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19	Dexamethasone	Anti-inflammatory	RCT	122	3
NCT04327401	COVID-19-associated ARDS Treated with Dexamethasone: Alliance Covid-19 Brasil III	Dexamethasone	Immune Suppression	RCT	290	3
NCT04358627	Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients	Dexmedetomidine	Immune Suppression	Case	80	N/A
NCT04355247	Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm	Corticosteroid	Immune Suppression	Single arm	20	2
NCT04360876	Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial	Steroids	Immune Suppression	RCT	90	2
NCT04323592	Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome	Methylprednisolone	Anti-inflammatory	CCT	104	3
NCT04343729	Methylprednisolone in the Treatment of Patients with Signs of Severe Acute Respiratory Syndrome in Covid-19	Methylprednisolone	Anti-inflammatory	RCT	420	2
NCT04306393	Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19	Nitric Oxide Gas	Pulmonary vasodilator	RCT	200	2
NCT04358588	Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19	Nitric Oxide	Anti-inflammation	N/A	N/A	N/A
NCT04244591	Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure	Glucocorticoid	Immune suppression	RCT	80	3
NCT04320277	Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.	Baricitinib	JAK inhibitor	CCT	60	3
NCT04340232	Safety and Efficacy of Baricitinib for COVID-19	Baricitinib	JAK inhibitor	Single arm	80	3
NCT04359290	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS	Ruxolitinib	JAK inhibitor	Single arm	15	2
NCT04355793	Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection	Ruxolitinib	JAK inhibitor	N/A	N/A	N/A
NCT04361903	Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection	Ruxolitinib	JAK inhibitor	Cohort	13	N/A
NCT04362137	Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)	Ruxolitinib	JAK inhibitor	RCT	402	3
NCT04321993	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	Baricitinib+ Sarilumab+Lopinavir/ritonavir+Hydroxychloroquine sulfate	JAK inhibitor+ Anti-IL-6+ Anti-virus+ Anti-inflammatory	CCT	1000	2
NCT04373044	Antiviral Therapy and Baricitinib for the Treatment of Patients With Moderate or Severe COVID-19	Antiviral Therapy+Baricitinib	Anti-virus+JAK inhibitor	Single arm	59	2
NCT04348383	Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.	Defibrotide	Anti-inflammatory	RCT	120	2
NCT04357444	Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19	IL-2	Anti-inflammation	RCT	30	2
NCT04355364	Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced ARDS (COVIDORNASE)	Aerosolized Intra-tracheal Dornase Alpha	Anti-inflammation	RCT	100	3
NCT04363437	COlchicine in Moderate Severity Hospitalized Patients Before ARDS to Treat COVID-19	Colchicine	Anti-inflammation	RCT	70	2
NCT04366791	Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19	Radiation	Other	Single arm	10	2

Register Number	Title	Drugs/Strategies	Therapeutic Target	Study design	Samples	Phase
ChiCTR2000029765	A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	RCT	188	4
ChiCTR2000030196	A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	Single arm	60	2
NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	Tocilizumab	Anti-IL-6 Receptor	Single arm	330	2
NCT04320615	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	330	3
NCT04310228	Favipiravir Combined with Tocilizumab in the Treatment of Corona Virus Disease 2019	Tocilizumab	Anti-IL-6 Receptor	RCT	150	N/A
NCT04306705	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19	Tocilizumab	Anti-IL-6 Receptor	Cohort study	120	N/A
NCT04315480	Tocilizumab for SARS-CoV2 Severe Pneumonitis	Tocilizumab	Anti-IL-6 Receptor	Single arm	30	2
NCT04331795	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	Tocilizumab	Anti-IL-6 Receptor	RCT	50	2
NCT04331808	CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)	Tocilizumab	Anti-IL-6 Receptor	RCT	240	2
NCT04332913	Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia	Tocilizumab	Anti-IL-6 Receptor	Cohort study	30	N/A
NCT04335071	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	RCT	100	2
NCT04346355	Efficacy of Early Administration of Tocilizumab in COVID-19 Patients	Tocilizumab	Anti-IL-6 Receptor	RCT	398	2
NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	Tocilizumab	Anti-IL-6 Receptor	RCT	300	3
NCT04359667	Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab	Tocilizumab	Anti-IL-6 Receptor	Case	30	N/A
NCT04361032	Assessment of Efficacy and Safety of Tocilizumab Compared to Deferoxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia	Tocilizumab/Deferoxamine	Anti-IL-6 Receptor	RCT	260	3
NCT04361552	Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)	Tocilizumab	Anti-IL-6 Receptor	RCT	180	3
NCT04363736	A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	100	2
NCT04363853	Tocilizumab Treatment in Patients With COVID-19	Tocilizumab	Anti-IL-6 Receptor	Single arm	200	2
NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	Tocilizumab	Anti-IL-6 Receptor	Single arm	200	2
NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	379	3
NCT04322773	Anti-il6 Treatment of Serious COVID-19 Disease with Threatening Respiratory Failure	Tocilizumab + Sarilumab	Anti-IL-6 Receptor	RCT	200	2
NCT04345445	Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients with High Risk of Progression	Tocilizumab or Corticosteroids	Anti-IL-6 Receptor Glucocorticoid	RCT	310	3
NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	Sarilumab	Anti-IL-6 Receptor	RCT	400	3
NCT04324073	Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI	Sarilumab	Anti-IL-6 Receptor	RCT	240	3
NCT04357808	Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)	Sarilumab	Anti-IL-6 Receptor	RCT	30	2
NCT04357860	Clinical Trial of Sarilumab in Adults With COVID-19	Sarilumab	Anti-IL-6 Receptor	RCT	120	2
NCT04359901	Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design	Sarilumab	Anti-IL-6 Receptor	RCT	120	2
NCT04322188	An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection	Siltuximab	Anti-IL-6	Case-Control	50	N/A
NCT04343989	A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients with Life-threatening COVID-19 Infection	Clazakizumab	Anti-IL-6	RCT	30	2
NCT04348500	Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease	Clazakizumab	Anti-IL-6	RCT	60	2
NCT04363502	Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	Clazakizumab	Anti-IL-6	RCT	30	2
ChiCTR2000030196	A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)	Conventional therapy+ Tocilizumab	Anti-IL-6R	Single arm	60	2
NCT04362813	Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia	Canakinumab	Anti-IL-1β	RCT	450	3
NCT04365153	Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19	Canakinumab	Anti-IL-1β	RCT	45	2
NCT04362111	Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19	Anakinra	Anti-IL-1 Receptor	RCT	20	3
NCT04357366	suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)	Anakinra or trimethoprim/sulfamethoxazole	Anti-IL-1 Receptor or Anti-inflammation	Single arm	100	2
NCT04364009	Anakinra for COVID-19 Respiratory Symptoms	Anakinra	Anti-IL-1 Receptor	RCT	240	3
NCT04366232	Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)	Anakinra+ Ruxolitinib	Anti-IL-1 Receptor+ JAK inhibitor	RCT	50	2
NCT04330638	Treatment of COVID-19 Patients with Anti-interleukin Drugs	Anakinra+ Siltuximab+ Tocilizumab	IL-1 receptor Antagonist+ Anti-IL-6+ Anti-IL-6 Receptor	RCT	342	3
ChiCTR2000030089	A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)	Adalimumab	Anti-TNF-alpha	RCT	60	4
ChiCTR2000030580	Efficacy and safety of adamumab combined with tozumab in severe and critical patients with novel coronavirus pneumonia (COVID-19)	Adalimumab and Tocilizumab	Anti-TNF-alpha Anti-IL-6 Receptor	RCT	60	4
NCT04324021	Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.	Emapalumab and Anakinra	Anti-IFN-γ IL-1 receptor Antagonist	RCT	54	3
ChiCTR2000030703	A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)	Ixekizumab	Anti-IL-17A	RCT	40	0
NCT04347226	Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19	BMS-986253	Anti-IL-8	RCT	138	2
NCT04275245	Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia	Humanized Meplazumab	Anti-CD147	Single arm	20	2
NCT04337216	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients with Severe COVID-19 Pneumonia and Systemic Hyper-inflammation	Mavrilimumab	Anti-GM-CSF-R	Single arm	10	2
NCT04341116	Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)	Anti-GM-CSF Monoclonal Antibody	Anti-GM-CSF	RCT	144	3
NCT04343651	Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19	Leronlimab	CCR5 blockading	RCT	75	2
NCT04347239	Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)	Leronlimab	CCR5 blockading	RCT	390	2
ChiCTR2000030262	Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)	type I interferon and TFF2	Boost innate resistance Anti-inflammatory peptide	RCT	30	0
ChiCTR2000029572	Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a randomized controlled clinical trial	Umbilical cord blood mononuclear cells	Anti-inflammatory, Anti-fibrotic	RCT	30	0
ChiCTR2000029606	Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)	Human Menstrual Blood-Derived Stem Cells	Anti-inflammatory, Anti-fibrotic	RCT	63	0
ChiCTR2000029990	Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)	Mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	RCT	120	2
ChiCTR2000030116	Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)	Human umbilical cord mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	CCT	16	N/A
ChiCTR2000030866	Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)	Human umbilical cord derived mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	Single arm	30	0
NCT04299152	Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2	Stem Cell	Immune suppression	RCT	20	2
NCT04333368	Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS	Umbilical Cord-derived Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	RCT	60	2
NCT04345601	Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)	Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	Single arm	30	1
NCT04361942	Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)	Allogeneic Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	RCT	24	2
NCT04366063	Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome	Mesenchymal Stem Cell	Anti-inflammatory, Anti-fibrotic	RCT	60	3
NCT04366830	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection	EAP+MSCs	Anti-inflammatory, Anti-fibrotic	N/A	N/A	N/A
NCT04371393	MSCs in COVID-19 ARDS	MSCs	Anti-inflammatory, Anti-fibrotic	RCT	300	3
ChiCTR2000029898	A Randomized, Open-label, Parallel, Controlled Trial for Evaluation of the Efficacy and Safety of Chloroquine Phosphate in the treatment of Severe Patients with Novel Coronavirus Pneumonia (COVID-19)	Chloroquine Phosphate	Immune suppression	RCT	100	4
NCT04323631	Hydroxychloroquine for the Treatment of Patients with Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	Hydroxychloroquine	Immune suppression	RCT	1116	1
NCT04323527	Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2	Chloroquine Diphosphate	Immune suppression	RCT	440	2
NCT04358068	Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19	Hydroxychloroquine +Azithromycin	Anti-inflammation	RCT	2000	2
NCT04358081	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease	Hydroxychloroquine+ Monotherapy+ Azithromycin	Anti-inflammation	RCT	444	3
NCT04362332	Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19	Chloroquine+ Hydroxychloroquine	Anti-inflammation	RCT	950	4
ChiCTR2000029757	Convalescent plasma for the treatment of severe novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial	Convalescent plasma	Convalescent plasma	RCT	200	0
ChiCTR2000029850	Study for convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)	Convalescent plasma	Convalescent plasma	CCT	20	0
ChiCTR2000030010	A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)	Anti-SARS-CoV-2 virus inactivated plasma	Convalescent plasma	RCT	100	N/A
ChiCTR2000030929	A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)	Anti-SARS-CoV-2 virus inactivated plasma	Convalescent plasma	RCT	60	N/A
NCT04346446	Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients	Convalescent Plasma in severe COVID-19 Patients	Convalescent Plasma	RCT	20	2
NCT04347681	Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19	Convalescent Plasma	Convalescent Plasma	CCT	40	2
NCT04353206	Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure	Convalescent Plasma in ICU Patients	Convalescent plasma	Single arm	90	1
NCT04359810	Plasma Therapy of COVID-19 in Critically Ill Patients	Convalescent Plasma	Convalescent plasma	RCT	105	2
ChiCTR2000030475	Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)	Cytosorb	Broad Cytokine/Toxin Removal	Single arm	19	0
NCT04324528	Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	Cytokine Adsorption+ Extracorporeal Membrane Oxygenation	Broad Cytokine/Toxin Removal	Case reports	30	R/A
NCT04344080	Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19	CytoSorb	Broad Cytokine/Toxin Removal	RCT	24	N/A
NCT04358003	Plasma Adsorption in Patients With Confirmed COVID-19	Plasma Adsorption	Broad Cytokine/Toxin Removal	Single arm	2000	N/A
NCT04374149	Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS	Plasma Exchange	Broad Cytokine/Toxin Removal	CCT	20	2
NCT04374539	Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial	Plasma Exchange	Broad Cytokine/Toxin Removal	RCT	116	2
NCT04273581	The Efficacy and Safety of Thalidomide Combined with Low-dose Hormones in the Treatment of Severe COVID-19	Thalidomide and Interferon-alpha	Prevent lung injury Boost Innate resistance	RCT	40	2
NCT04293887	Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients	IFN-α2β	Boost Innate Resistance	RCT	328	1
NCT04343768	An Investigation into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial	Interferon Beta 1a or Interferon Beta 1b	Boost Innate Resistance	RCT	60	4
NCT04325061	Efficacy of Dexamethasone Treatment for Patients with ARDS Caused by COVID-19	Dexamethasone	Anti-inflammatory	RCT	200	4
NCT04347980	Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19	Dexamethasone	Anti-inflammatory	RCT	122	3
NCT04327401	COVID-19-associated ARDS Treated with Dexamethasone: Alliance Covid-19 Brasil III	Dexamethasone	Immune Suppression	RCT	290	3
NCT04358627	Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients	Dexmedetomidine	Immune Suppression	Case	80	N/A
NCT04355247	Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm	Corticosteroid	Immune Suppression	Single arm	20	2
NCT04360876	Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial	Steroids	Immune Suppression	RCT	90	2
NCT04323592	Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome	Methylprednisolone	Anti-inflammatory	CCT	104	3
NCT04343729	Methylprednisolone in the Treatment of Patients with Signs of Severe Acute Respiratory Syndrome in Covid-19	Methylprednisolone	Anti-inflammatory	RCT	420	2
NCT04306393	Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19	Nitric Oxide Gas	Pulmonary vasodilator	RCT	200	2
NCT04358588	Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19	Nitric Oxide	Anti-inflammation	N/A	N/A	N/A
NCT04244591	Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure	Glucocorticoid	Immune suppression	RCT	80	3
NCT04320277	Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.	Baricitinib	JAK inhibitor	CCT	60	3
NCT04340232	Safety and Efficacy of Baricitinib for COVID-19	Baricitinib	JAK inhibitor	Single arm	80	3
NCT04359290	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS	Ruxolitinib	JAK inhibitor	Single arm	15	2
NCT04355793	Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection	Ruxolitinib	JAK inhibitor	N/A	N/A	N/A
NCT04361903	Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection	Ruxolitinib	JAK inhibitor	Cohort	13	N/A
NCT04362137	Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)	Ruxolitinib	JAK inhibitor	RCT	402	3
NCT04321993	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	Baricitinib+ Sarilumab+Lopinavir/ritonavir+Hydroxychloroquine sulfate	JAK inhibitor+ Anti-IL-6+ Anti-virus+ Anti-inflammatory	CCT	1000	2
NCT04373044	Antiviral Therapy and Baricitinib for the Treatment of Patients With Moderate or Severe COVID-19	Antiviral Therapy+Baricitinib	Anti-virus+JAK inhibitor	Single arm	59	2
NCT04348383	Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.	Defibrotide	Anti-inflammatory	RCT	120	2
NCT04357444	Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19	IL-2	Anti-inflammation	RCT	30	2
NCT04355364	Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced ARDS (COVIDORNASE)	Aerosolized Intra-tracheal Dornase Alpha	Anti-inflammation	RCT	100	3
NCT04363437	COlchicine in Moderate Severity Hospitalized Patients Before ARDS to Treat COVID-19	Colchicine	Anti-inflammation	RCT	70	2
NCT04366791	Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19	Radiation	Other	Single arm	10	2

Abbrevation: ChiCTR, Chinese Clinical Trials Register; NCT, National Clinical Trails; RCT: Random clinical trial; CCT: Controlled clinical trial;

TABLE 2

Open in new tab

Ongoing Clinical Trials: therapeutics against cytokine storm (up to May 6, 2020)

Register Number	Title	Drugs/Strategies	Therapeutic Target	Study design	Samples	Phase
ChiCTR2000029765	A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	RCT	188	4
ChiCTR2000030196	A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	Single arm	60	2
NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	Tocilizumab	Anti-IL-6 Receptor	Single arm	330	2
NCT04320615	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	330	3
NCT04310228	Favipiravir Combined with Tocilizumab in the Treatment of Corona Virus Disease 2019	Tocilizumab	Anti-IL-6 Receptor	RCT	150	N/A
NCT04306705	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19	Tocilizumab	Anti-IL-6 Receptor	Cohort study	120	N/A
NCT04315480	Tocilizumab for SARS-CoV2 Severe Pneumonitis	Tocilizumab	Anti-IL-6 Receptor	Single arm	30	2
NCT04331795	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	Tocilizumab	Anti-IL-6 Receptor	RCT	50	2
NCT04331808	CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)	Tocilizumab	Anti-IL-6 Receptor	RCT	240	2
NCT04332913	Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia	Tocilizumab	Anti-IL-6 Receptor	Cohort study	30	N/A
NCT04335071	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	RCT	100	2
NCT04346355	Efficacy of Early Administration of Tocilizumab in COVID-19 Patients	Tocilizumab	Anti-IL-6 Receptor	RCT	398	2
NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	Tocilizumab	Anti-IL-6 Receptor	RCT	300	3
NCT04359667	Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab	Tocilizumab	Anti-IL-6 Receptor	Case	30	N/A
NCT04361032	Assessment of Efficacy and Safety of Tocilizumab Compared to Deferoxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia	Tocilizumab/Deferoxamine	Anti-IL-6 Receptor	RCT	260	3
NCT04361552	Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)	Tocilizumab	Anti-IL-6 Receptor	RCT	180	3
NCT04363736	A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	100	2
NCT04363853	Tocilizumab Treatment in Patients With COVID-19	Tocilizumab	Anti-IL-6 Receptor	Single arm	200	2
NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	Tocilizumab	Anti-IL-6 Receptor	Single arm	200	2
NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	379	3
NCT04322773	Anti-il6 Treatment of Serious COVID-19 Disease with Threatening Respiratory Failure	Tocilizumab + Sarilumab	Anti-IL-6 Receptor	RCT	200	2
NCT04345445	Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients with High Risk of Progression	Tocilizumab or Corticosteroids	Anti-IL-6 Receptor Glucocorticoid	RCT	310	3
NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	Sarilumab	Anti-IL-6 Receptor	RCT	400	3
NCT04324073	Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI	Sarilumab	Anti-IL-6 Receptor	RCT	240	3
NCT04357808	Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)	Sarilumab	Anti-IL-6 Receptor	RCT	30	2
NCT04357860	Clinical Trial of Sarilumab in Adults With COVID-19	Sarilumab	Anti-IL-6 Receptor	RCT	120	2
NCT04359901	Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design	Sarilumab	Anti-IL-6 Receptor	RCT	120	2
NCT04322188	An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection	Siltuximab	Anti-IL-6	Case-Control	50	N/A
NCT04343989	A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients with Life-threatening COVID-19 Infection	Clazakizumab	Anti-IL-6	RCT	30	2
NCT04348500	Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease	Clazakizumab	Anti-IL-6	RCT	60	2
NCT04363502	Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	Clazakizumab	Anti-IL-6	RCT	30	2
ChiCTR2000030196	A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)	Conventional therapy+ Tocilizumab	Anti-IL-6R	Single arm	60	2
NCT04362813	Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia	Canakinumab	Anti-IL-1β	RCT	450	3
NCT04365153	Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19	Canakinumab	Anti-IL-1β	RCT	45	2
NCT04362111	Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19	Anakinra	Anti-IL-1 Receptor	RCT	20	3
NCT04357366	suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)	Anakinra or trimethoprim/sulfamethoxazole	Anti-IL-1 Receptor or Anti-inflammation	Single arm	100	2
NCT04364009	Anakinra for COVID-19 Respiratory Symptoms	Anakinra	Anti-IL-1 Receptor	RCT	240	3
NCT04366232	Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)	Anakinra+ Ruxolitinib	Anti-IL-1 Receptor+ JAK inhibitor	RCT	50	2
NCT04330638	Treatment of COVID-19 Patients with Anti-interleukin Drugs	Anakinra+ Siltuximab+ Tocilizumab	IL-1 receptor Antagonist+ Anti-IL-6+ Anti-IL-6 Receptor	RCT	342	3
ChiCTR2000030089	A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)	Adalimumab	Anti-TNF-alpha	RCT	60	4
ChiCTR2000030580	Efficacy and safety of adamumab combined with tozumab in severe and critical patients with novel coronavirus pneumonia (COVID-19)	Adalimumab and Tocilizumab	Anti-TNF-alpha Anti-IL-6 Receptor	RCT	60	4
NCT04324021	Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.	Emapalumab and Anakinra	Anti-IFN-γ IL-1 receptor Antagonist	RCT	54	3
ChiCTR2000030703	A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)	Ixekizumab	Anti-IL-17A	RCT	40	0
NCT04347226	Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19	BMS-986253	Anti-IL-8	RCT	138	2
NCT04275245	Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia	Humanized Meplazumab	Anti-CD147	Single arm	20	2
NCT04337216	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients with Severe COVID-19 Pneumonia and Systemic Hyper-inflammation	Mavrilimumab	Anti-GM-CSF-R	Single arm	10	2
NCT04341116	Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)	Anti-GM-CSF Monoclonal Antibody	Anti-GM-CSF	RCT	144	3
NCT04343651	Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19	Leronlimab	CCR5 blockading	RCT	75	2
NCT04347239	Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)	Leronlimab	CCR5 blockading	RCT	390	2
ChiCTR2000030262	Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)	type I interferon and TFF2	Boost innate resistance Anti-inflammatory peptide	RCT	30	0
ChiCTR2000029572	Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a randomized controlled clinical trial	Umbilical cord blood mononuclear cells	Anti-inflammatory, Anti-fibrotic	RCT	30	0
ChiCTR2000029606	Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)	Human Menstrual Blood-Derived Stem Cells	Anti-inflammatory, Anti-fibrotic	RCT	63	0
ChiCTR2000029990	Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)	Mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	RCT	120	2
ChiCTR2000030116	Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)	Human umbilical cord mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	CCT	16	N/A
ChiCTR2000030866	Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)	Human umbilical cord derived mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	Single arm	30	0
NCT04299152	Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2	Stem Cell	Immune suppression	RCT	20	2
NCT04333368	Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS	Umbilical Cord-derived Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	RCT	60	2
NCT04345601	Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)	Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	Single arm	30	1
NCT04361942	Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)	Allogeneic Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	RCT	24	2
NCT04366063	Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome	Mesenchymal Stem Cell	Anti-inflammatory, Anti-fibrotic	RCT	60	3
NCT04366830	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection	EAP+MSCs	Anti-inflammatory, Anti-fibrotic	N/A	N/A	N/A
NCT04371393	MSCs in COVID-19 ARDS	MSCs	Anti-inflammatory, Anti-fibrotic	RCT	300	3
ChiCTR2000029898	A Randomized, Open-label, Parallel, Controlled Trial for Evaluation of the Efficacy and Safety of Chloroquine Phosphate in the treatment of Severe Patients with Novel Coronavirus Pneumonia (COVID-19)	Chloroquine Phosphate	Immune suppression	RCT	100	4
NCT04323631	Hydroxychloroquine for the Treatment of Patients with Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	Hydroxychloroquine	Immune suppression	RCT	1116	1
NCT04323527	Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2	Chloroquine Diphosphate	Immune suppression	RCT	440	2
NCT04358068	Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19	Hydroxychloroquine +Azithromycin	Anti-inflammation	RCT	2000	2
NCT04358081	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease	Hydroxychloroquine+ Monotherapy+ Azithromycin	Anti-inflammation	RCT	444	3
NCT04362332	Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19	Chloroquine+ Hydroxychloroquine	Anti-inflammation	RCT	950	4
ChiCTR2000029757	Convalescent plasma for the treatment of severe novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial	Convalescent plasma	Convalescent plasma	RCT	200	0
ChiCTR2000029850	Study for convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)	Convalescent plasma	Convalescent plasma	CCT	20	0
ChiCTR2000030010	A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)	Anti-SARS-CoV-2 virus inactivated plasma	Convalescent plasma	RCT	100	N/A
ChiCTR2000030929	A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)	Anti-SARS-CoV-2 virus inactivated plasma	Convalescent plasma	RCT	60	N/A
NCT04346446	Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients	Convalescent Plasma in severe COVID-19 Patients	Convalescent Plasma	RCT	20	2
NCT04347681	Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19	Convalescent Plasma	Convalescent Plasma	CCT	40	2
NCT04353206	Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure	Convalescent Plasma in ICU Patients	Convalescent plasma	Single arm	90	1
NCT04359810	Plasma Therapy of COVID-19 in Critically Ill Patients	Convalescent Plasma	Convalescent plasma	RCT	105	2
ChiCTR2000030475	Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)	Cytosorb	Broad Cytokine/Toxin Removal	Single arm	19	0
NCT04324528	Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	Cytokine Adsorption+ Extracorporeal Membrane Oxygenation	Broad Cytokine/Toxin Removal	Case reports	30	R/A
NCT04344080	Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19	CytoSorb	Broad Cytokine/Toxin Removal	RCT	24	N/A
NCT04358003	Plasma Adsorption in Patients With Confirmed COVID-19	Plasma Adsorption	Broad Cytokine/Toxin Removal	Single arm	2000	N/A
NCT04374149	Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS	Plasma Exchange	Broad Cytokine/Toxin Removal	CCT	20	2
NCT04374539	Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial	Plasma Exchange	Broad Cytokine/Toxin Removal	RCT	116	2
NCT04273581	The Efficacy and Safety of Thalidomide Combined with Low-dose Hormones in the Treatment of Severe COVID-19	Thalidomide and Interferon-alpha	Prevent lung injury Boost Innate resistance	RCT	40	2
NCT04293887	Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients	IFN-α2β	Boost Innate Resistance	RCT	328	1
NCT04343768	An Investigation into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial	Interferon Beta 1a or Interferon Beta 1b	Boost Innate Resistance	RCT	60	4
NCT04325061	Efficacy of Dexamethasone Treatment for Patients with ARDS Caused by COVID-19	Dexamethasone	Anti-inflammatory	RCT	200	4
NCT04347980	Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19	Dexamethasone	Anti-inflammatory	RCT	122	3
NCT04327401	COVID-19-associated ARDS Treated with Dexamethasone: Alliance Covid-19 Brasil III	Dexamethasone	Immune Suppression	RCT	290	3
NCT04358627	Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients	Dexmedetomidine	Immune Suppression	Case	80	N/A
NCT04355247	Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm	Corticosteroid	Immune Suppression	Single arm	20	2
NCT04360876	Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial	Steroids	Immune Suppression	RCT	90	2
NCT04323592	Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome	Methylprednisolone	Anti-inflammatory	CCT	104	3
NCT04343729	Methylprednisolone in the Treatment of Patients with Signs of Severe Acute Respiratory Syndrome in Covid-19	Methylprednisolone	Anti-inflammatory	RCT	420	2
NCT04306393	Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19	Nitric Oxide Gas	Pulmonary vasodilator	RCT	200	2
NCT04358588	Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19	Nitric Oxide	Anti-inflammation	N/A	N/A	N/A
NCT04244591	Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure	Glucocorticoid	Immune suppression	RCT	80	3
NCT04320277	Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.	Baricitinib	JAK inhibitor	CCT	60	3
NCT04340232	Safety and Efficacy of Baricitinib for COVID-19	Baricitinib	JAK inhibitor	Single arm	80	3
NCT04359290	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS	Ruxolitinib	JAK inhibitor	Single arm	15	2
NCT04355793	Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection	Ruxolitinib	JAK inhibitor	N/A	N/A	N/A
NCT04361903	Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection	Ruxolitinib	JAK inhibitor	Cohort	13	N/A
NCT04362137	Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)	Ruxolitinib	JAK inhibitor	RCT	402	3
NCT04321993	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	Baricitinib+ Sarilumab+Lopinavir/ritonavir+Hydroxychloroquine sulfate	JAK inhibitor+ Anti-IL-6+ Anti-virus+ Anti-inflammatory	CCT	1000	2
NCT04373044	Antiviral Therapy and Baricitinib for the Treatment of Patients With Moderate or Severe COVID-19	Antiviral Therapy+Baricitinib	Anti-virus+JAK inhibitor	Single arm	59	2
NCT04348383	Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.	Defibrotide	Anti-inflammatory	RCT	120	2
NCT04357444	Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19	IL-2	Anti-inflammation	RCT	30	2
NCT04355364	Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced ARDS (COVIDORNASE)	Aerosolized Intra-tracheal Dornase Alpha	Anti-inflammation	RCT	100	3
NCT04363437	COlchicine in Moderate Severity Hospitalized Patients Before ARDS to Treat COVID-19	Colchicine	Anti-inflammation	RCT	70	2
NCT04366791	Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19	Radiation	Other	Single arm	10	2

Register Number	Title	Drugs/Strategies	Therapeutic Target	Study design	Samples	Phase
ChiCTR2000029765	A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	RCT	188	4
ChiCTR2000030196	A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	Single arm	60	2
NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	Tocilizumab	Anti-IL-6 Receptor	Single arm	330	2
NCT04320615	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	330	3
NCT04310228	Favipiravir Combined with Tocilizumab in the Treatment of Corona Virus Disease 2019	Tocilizumab	Anti-IL-6 Receptor	RCT	150	N/A
NCT04306705	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19	Tocilizumab	Anti-IL-6 Receptor	Cohort study	120	N/A
NCT04315480	Tocilizumab for SARS-CoV2 Severe Pneumonitis	Tocilizumab	Anti-IL-6 Receptor	Single arm	30	2
NCT04331795	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	Tocilizumab	Anti-IL-6 Receptor	RCT	50	2
NCT04331808	CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)	Tocilizumab	Anti-IL-6 Receptor	RCT	240	2
NCT04332913	Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia	Tocilizumab	Anti-IL-6 Receptor	Cohort study	30	N/A
NCT04335071	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)	Tocilizumab	Anti-IL-6 Receptor	RCT	100	2
NCT04346355	Efficacy of Early Administration of Tocilizumab in COVID-19 Patients	Tocilizumab	Anti-IL-6 Receptor	RCT	398	2
NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	Tocilizumab	Anti-IL-6 Receptor	RCT	300	3
NCT04359667	Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab	Tocilizumab	Anti-IL-6 Receptor	Case	30	N/A
NCT04361032	Assessment of Efficacy and Safety of Tocilizumab Compared to Deferoxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia	Tocilizumab/Deferoxamine	Anti-IL-6 Receptor	RCT	260	3
NCT04361552	Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)	Tocilizumab	Anti-IL-6 Receptor	RCT	180	3
NCT04363736	A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	100	2
NCT04363853	Tocilizumab Treatment in Patients With COVID-19	Tocilizumab	Anti-IL-6 Receptor	Single arm	200	2
NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	Tocilizumab	Anti-IL-6 Receptor	Single arm	200	2
NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia	Tocilizumab	Anti-IL-6 Receptor	RCT	379	3
NCT04322773	Anti-il6 Treatment of Serious COVID-19 Disease with Threatening Respiratory Failure	Tocilizumab + Sarilumab	Anti-IL-6 Receptor	RCT	200	2
NCT04345445	Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients with High Risk of Progression	Tocilizumab or Corticosteroids	Anti-IL-6 Receptor Glucocorticoid	RCT	310	3
NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	Sarilumab	Anti-IL-6 Receptor	RCT	400	3
NCT04324073	Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI	Sarilumab	Anti-IL-6 Receptor	RCT	240	3
NCT04357808	Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)	Sarilumab	Anti-IL-6 Receptor	RCT	30	2
NCT04357860	Clinical Trial of Sarilumab in Adults With COVID-19	Sarilumab	Anti-IL-6 Receptor	RCT	120	2
NCT04359901	Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design	Sarilumab	Anti-IL-6 Receptor	RCT	120	2
NCT04322188	An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection	Siltuximab	Anti-IL-6	Case-Control	50	N/A
NCT04343989	A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients with Life-threatening COVID-19 Infection	Clazakizumab	Anti-IL-6	RCT	30	2
NCT04348500	Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease	Clazakizumab	Anti-IL-6	RCT	60	2
NCT04363502	Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	Clazakizumab	Anti-IL-6	RCT	30	2
ChiCTR2000030196	A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)	Conventional therapy+ Tocilizumab	Anti-IL-6R	Single arm	60	2
NCT04362813	Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia	Canakinumab	Anti-IL-1β	RCT	450	3
NCT04365153	Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19	Canakinumab	Anti-IL-1β	RCT	45	2
NCT04362111	Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19	Anakinra	Anti-IL-1 Receptor	RCT	20	3
NCT04357366	suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)	Anakinra or trimethoprim/sulfamethoxazole	Anti-IL-1 Receptor or Anti-inflammation	Single arm	100	2
NCT04364009	Anakinra for COVID-19 Respiratory Symptoms	Anakinra	Anti-IL-1 Receptor	RCT	240	3
NCT04366232	Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)	Anakinra+ Ruxolitinib	Anti-IL-1 Receptor+ JAK inhibitor	RCT	50	2
NCT04330638	Treatment of COVID-19 Patients with Anti-interleukin Drugs	Anakinra+ Siltuximab+ Tocilizumab	IL-1 receptor Antagonist+ Anti-IL-6+ Anti-IL-6 Receptor	RCT	342	3
ChiCTR2000030089	A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)	Adalimumab	Anti-TNF-alpha	RCT	60	4
ChiCTR2000030580	Efficacy and safety of adamumab combined with tozumab in severe and critical patients with novel coronavirus pneumonia (COVID-19)	Adalimumab and Tocilizumab	Anti-TNF-alpha Anti-IL-6 Receptor	RCT	60	4
NCT04324021	Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.	Emapalumab and Anakinra	Anti-IFN-γ IL-1 receptor Antagonist	RCT	54	3
ChiCTR2000030703	A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)	Ixekizumab	Anti-IL-17A	RCT	40	0
NCT04347226	Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19	BMS-986253	Anti-IL-8	RCT	138	2
NCT04275245	Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia	Humanized Meplazumab	Anti-CD147	Single arm	20	2
NCT04337216	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients with Severe COVID-19 Pneumonia and Systemic Hyper-inflammation	Mavrilimumab	Anti-GM-CSF-R	Single arm	10	2
NCT04341116	Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)	Anti-GM-CSF Monoclonal Antibody	Anti-GM-CSF	RCT	144	3
NCT04343651	Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19	Leronlimab	CCR5 blockading	RCT	75	2
NCT04347239	Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)	Leronlimab	CCR5 blockading	RCT	390	2
ChiCTR2000030262	Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)	type I interferon and TFF2	Boost innate resistance Anti-inflammatory peptide	RCT	30	0
ChiCTR2000029572	Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a randomized controlled clinical trial	Umbilical cord blood mononuclear cells	Anti-inflammatory, Anti-fibrotic	RCT	30	0
ChiCTR2000029606	Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)	Human Menstrual Blood-Derived Stem Cells	Anti-inflammatory, Anti-fibrotic	RCT	63	0
ChiCTR2000029990	Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)	Mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	RCT	120	2
ChiCTR2000030116	Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)	Human umbilical cord mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	CCT	16	N/A
ChiCTR2000030866	Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)	Human umbilical cord derived mesenchymal stem cells	Anti-inflammatory, Anti-fibrotic	Single arm	30	0
NCT04299152	Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2	Stem Cell	Immune suppression	RCT	20	2
NCT04333368	Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS	Umbilical Cord-derived Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	RCT	60	2
NCT04345601	Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)	Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	Single arm	30	1
NCT04361942	Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)	Allogeneic Mesenchymal Stromal Cells	Anti-inflammatory, Anti-fibrotic	RCT	24	2
NCT04366063	Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome	Mesenchymal Stem Cell	Anti-inflammatory, Anti-fibrotic	RCT	60	3
NCT04366830	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection	EAP+MSCs	Anti-inflammatory, Anti-fibrotic	N/A	N/A	N/A
NCT04371393	MSCs in COVID-19 ARDS	MSCs	Anti-inflammatory, Anti-fibrotic	RCT	300	3
ChiCTR2000029898	A Randomized, Open-label, Parallel, Controlled Trial for Evaluation of the Efficacy and Safety of Chloroquine Phosphate in the treatment of Severe Patients with Novel Coronavirus Pneumonia (COVID-19)	Chloroquine Phosphate	Immune suppression	RCT	100	4
NCT04323631	Hydroxychloroquine for the Treatment of Patients with Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	Hydroxychloroquine	Immune suppression	RCT	1116	1
NCT04323527	Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2	Chloroquine Diphosphate	Immune suppression	RCT	440	2
NCT04358068	Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19	Hydroxychloroquine +Azithromycin	Anti-inflammation	RCT	2000	2
NCT04358081	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease	Hydroxychloroquine+ Monotherapy+ Azithromycin	Anti-inflammation	RCT	444	3
NCT04362332	Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19	Chloroquine+ Hydroxychloroquine	Anti-inflammation	RCT	950	4
ChiCTR2000029757	Convalescent plasma for the treatment of severe novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial	Convalescent plasma	Convalescent plasma	RCT	200	0
ChiCTR2000029850	Study for convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)	Convalescent plasma	Convalescent plasma	CCT	20	0
ChiCTR2000030010	A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)	Anti-SARS-CoV-2 virus inactivated plasma	Convalescent plasma	RCT	100	N/A
ChiCTR2000030929	A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)	Anti-SARS-CoV-2 virus inactivated plasma	Convalescent plasma	RCT	60	N/A
NCT04346446	Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients	Convalescent Plasma in severe COVID-19 Patients	Convalescent Plasma	RCT	20	2
NCT04347681	Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19	Convalescent Plasma	Convalescent Plasma	CCT	40	2
NCT04353206	Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure	Convalescent Plasma in ICU Patients	Convalescent plasma	Single arm	90	1
NCT04359810	Plasma Therapy of COVID-19 in Critically Ill Patients	Convalescent Plasma	Convalescent plasma	RCT	105	2
ChiCTR2000030475	Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)	Cytosorb	Broad Cytokine/Toxin Removal	Single arm	19	0
NCT04324528	Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	Cytokine Adsorption+ Extracorporeal Membrane Oxygenation	Broad Cytokine/Toxin Removal	Case reports	30	R/A
NCT04344080	Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19	CytoSorb	Broad Cytokine/Toxin Removal	RCT	24	N/A
NCT04358003	Plasma Adsorption in Patients With Confirmed COVID-19	Plasma Adsorption	Broad Cytokine/Toxin Removal	Single arm	2000	N/A
NCT04374149	Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS	Plasma Exchange	Broad Cytokine/Toxin Removal	CCT	20	2
NCT04374539	Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial	Plasma Exchange	Broad Cytokine/Toxin Removal	RCT	116	2
NCT04273581	The Efficacy and Safety of Thalidomide Combined with Low-dose Hormones in the Treatment of Severe COVID-19	Thalidomide and Interferon-alpha	Prevent lung injury Boost Innate resistance	RCT	40	2
NCT04293887	Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients	IFN-α2β	Boost Innate Resistance	RCT	328	1
NCT04343768	An Investigation into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial	Interferon Beta 1a or Interferon Beta 1b	Boost Innate Resistance	RCT	60	4
NCT04325061	Efficacy of Dexamethasone Treatment for Patients with ARDS Caused by COVID-19	Dexamethasone	Anti-inflammatory	RCT	200	4
NCT04347980	Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19	Dexamethasone	Anti-inflammatory	RCT	122	3
NCT04327401	COVID-19-associated ARDS Treated with Dexamethasone: Alliance Covid-19 Brasil III	Dexamethasone	Immune Suppression	RCT	290	3
NCT04358627	Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients	Dexmedetomidine	Immune Suppression	Case	80	N/A
NCT04355247	Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm	Corticosteroid	Immune Suppression	Single arm	20	2
NCT04360876	Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial	Steroids	Immune Suppression	RCT	90	2
NCT04323592	Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome	Methylprednisolone	Anti-inflammatory	CCT	104	3
NCT04343729	Methylprednisolone in the Treatment of Patients with Signs of Severe Acute Respiratory Syndrome in Covid-19	Methylprednisolone	Anti-inflammatory	RCT	420	2
NCT04306393	Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19	Nitric Oxide Gas	Pulmonary vasodilator	RCT	200	2
NCT04358588	Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19	Nitric Oxide	Anti-inflammation	N/A	N/A	N/A
NCT04244591	Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure	Glucocorticoid	Immune suppression	RCT	80	3
NCT04320277	Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.	Baricitinib	JAK inhibitor	CCT	60	3
NCT04340232	Safety and Efficacy of Baricitinib for COVID-19	Baricitinib	JAK inhibitor	Single arm	80	3
NCT04359290	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS	Ruxolitinib	JAK inhibitor	Single arm	15	2
NCT04355793	Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection	Ruxolitinib	JAK inhibitor	N/A	N/A	N/A
NCT04361903	Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection	Ruxolitinib	JAK inhibitor	Cohort	13	N/A
NCT04362137	Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)	Ruxolitinib	JAK inhibitor	RCT	402	3
NCT04321993	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	Baricitinib+ Sarilumab+Lopinavir/ritonavir+Hydroxychloroquine sulfate	JAK inhibitor+ Anti-IL-6+ Anti-virus+ Anti-inflammatory	CCT	1000	2
NCT04373044	Antiviral Therapy and Baricitinib for the Treatment of Patients With Moderate or Severe COVID-19	Antiviral Therapy+Baricitinib	Anti-virus+JAK inhibitor	Single arm	59	2
NCT04348383	Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.	Defibrotide	Anti-inflammatory	RCT	120	2
NCT04357444	Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19	IL-2	Anti-inflammation	RCT	30	2
NCT04355364	Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced ARDS (COVIDORNASE)	Aerosolized Intra-tracheal Dornase Alpha	Anti-inflammation	RCT	100	3
NCT04363437	COlchicine in Moderate Severity Hospitalized Patients Before ARDS to Treat COVID-19	Colchicine	Anti-inflammation	RCT	70	2
NCT04366791	Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19	Radiation	Other	Single arm	10	2

Abbrevation: ChiCTR, Chinese Clinical Trials Register; NCT, National Clinical Trails; RCT: Random clinical trial; CCT: Controlled clinical trial;

This Feature Is Available To Subscribers Only